In TNBC, the combining chemotherapy paclitaxel with PD-L1 checkpoint inhibitors atezolizumab did not benefit all patients [41,42]; to illuminate the different immune responses in TNBC patients (22 patients with TNBC pre- and on-treated with paclitaxel or its combination with atezolizumab), Zhang et al. leveraged single-cell multi-omics to investigate the dynamic map of tumor microenvironment and immune cells derived from peripheral blood. Here, CD274 is linked to neoplasm.